Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Kobayashi Pharmaceutical Co's average EPS without NRIGrowth Rate was -30.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -5.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -1.70% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 4.70% per year.
During the past 13 years, Kobayashi Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 19.90% per year. The lowest was -13.40% per year. And the median was 1.00% per year.
Kobayashi Pharmaceutical Co (FRA:KOY) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Kobayashi Pharmaceutical Co Earnings per Share (Diluted) Related Terms
Kobayashi Pharmaceutical Co Earnings per Share (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kobayashi Pharmaceutical Co Earnings per Share (Diluted) Chart
FRA:KOY vs PG, CL, EL: Earnings per Share (Diluted) Comparison
For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kobayashi Pharmaceutical Co PE Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Kobayashi Pharmaceutical Co's PE Ratio falls into.
Kobayashi Pharmaceutical Co Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Kobayashi Pharmaceutical Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €0.25 mean?
Kobayashi Pharmaceutical Co (FRA:KOY) has a Earnings per Share (Diluted) of €0.25 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Kobayashi Pharmaceutical Co and its competitors. According to the industry distribution chart, Kobayashi Pharmaceutical Co ranks #1037 out of 1533 companies in the Consumer Packaged Goods industry, placing it in the top 67.6%.
Is Kobayashi Pharmaceutical Co's Earnings per Share (Diluted) too high?
Kobayashi Pharmaceutical Co's current Earnings per Share (Diluted) is €0.25. Based on the distribution chart, Kobayashi Pharmaceutical Co ranks #1037 out of 1533 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Kobayashi Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kobayashi Pharmaceutical Co's Earnings per Share (Diluted) compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Kobayashi Pharmaceutical Co ranks #1037 out of 1533 companies for Earnings per Share (Diluted). This places Kobayashi Pharmaceutical Co in the lower half of its industry. The industry median Earnings per Share (Diluted) is 7.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Consumer Packaged Goods company?
The median Earnings per Share (Diluted) among Consumer Packaged Goods companies is 7.20, based on 1,533 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Kobayashi Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Earnings per Share (Diluted) is 7.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kobayashi Pharmaceutical Co's current Earnings per Share (Diluted) is €0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobayashi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co (FRA:KOY) is currently considered Modestly Overvalued. The stock's GF Value™ is €26.16, compared to a current price of €30.40 — trading 16.2% above its estimated fair value. The current Earnings per Share (Diluted) is €0.25. Kobayashi Pharmaceutical Co's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Kobayashi Pharmaceutical Co (FRA:KOY), the current Earnings per Share (Diluted) is €0.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kobayashi Pharmaceutical Co (FRA:KOY) Overvalued in 2026?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued.
The current stock price of €30.40 is trading 16.2% above its estimated GF Value™ of €26.16.
GuruFocus considers Kobayashi Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for FRA:KOY:
Earnings per Share (Diluted): €0.25
GF Value™: €26.16 vs. price of €30.40 (16.2% above fair value)
No single metric tells the full story. See the FRA:KOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
77GF Score
Get the complete analysis for FRA:KOY
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KOY has been successfully added to your 
